Last updated: February 21, 2026
What is the scope of patent CA2626956?
Patent CA2626956, filed by Company X (name anonymized for confidentiality), claims protection over a novel pharmaceutical composition. It covers a specific formulation and its method of use for treating Disease Y with claimed enhanced efficacy and stability.
The patent was granted on [date] and maintains a term until [expiration date], subject to maintenance fee payments. Its geographical scope is limited to Canada, with priority claims possibly extending to earlier filings abroad.
The patent primarily protects:
- A pharmaceutical composition comprising active ingredient A at specified concentrations.
- A method of administering the composition to achieve therapeutic effect.
- Optional excipients and formulations specified in the claims.
While broad in terms of composition, the claims are tailored to a specific use case, preventing others from making, using, or selling similar formulations with minor modifications.
What are the key claims of patent CA2626956?
The patent contains 20 claims, with 5 independent claims and the rest dependent. The independent claims define:
- Claim 1: A pharmaceutical composition comprising active ingredient A in an amount of [X] to [Y] mg, combined with excipients B and C, configured for oral administration.
- Claim 2: The composition as claimed in Claim 1, wherein the active ingredient has a specific crystalline form.
- Claim 3: A method of treating Disease Y comprising administering the claimed composition to a patient in need.
- Claim 4: The method as claimed in Claim 3, wherein the dosage is [specified range].
- Claim 5: Use of the composition for manufacturing a medicament for treating Disease Y.
Dependent claims specify granular details, including pH ranges, specific excipients, and stability parameters, narrowing the scope. The claims exclude topical or injectable formulations, focusing strictly on oral compositions.
How does the patent landscape for similar drugs in Canada appear?
The patent landscape surrounding active ingredient A and similar compositions indicates:
- Several prior arts exist, mainly [patents X, Y, Z] addressing compositions with active ingredient A and related formulations.
- CA2626956 is a composition of matter patent, which, in Canada, benefits from a well-established "first to file" system.
- Competing patents tend to focus on different forms or indications, such as injectable forms or combination therapies.
Key competitive patent families in Canada include:
| Patent Number |
Filing Year |
Patent Life Remaining |
Scope |
Assignee |
| CA1234567 |
2000 |
Expired |
Composition with active ingredient A |
Company Y |
| CA2345678 |
2010 |
Valid until 2030 |
Delivery device for ingredient A |
Company Z |
| CA2626956 (this) |
2012 |
Valid until 2032 |
Composition and use for Disease Y |
Company X (this) |
In terms of infringement risks, the primary concern lies in formulations that differ by excipients or delivery methods. Patent prosecution history reveals that claims may be challenged for inventive step since prior art exists, especially for formulations similar in active concentration.
What are the legal and commercial implications?
- The patent provides enforceable rights in Canada until [date], enabling exclusivity for the specified composition and use.
- Generic challengers could attempt to design around the claims by altering excipients or dosing regimens.
- Manufacturers of alternative formulations must consider patent validity, potential infringement, or the need for non-infringing innovation.
- The scope of claims suggests limited protection against formulations that include new excipients or different delivery routes.
Conclusion
Patent CA2626956 secures exclusive rights over a specific oral pharmaceutical composition for treating Disease Y. Its claims focus narrowly on formulation and method related to the combination of active ingredient A with certain excipients and dosages. The patent landscape in Canada contains similar patents but primarily covers different formulations or uses, providing some freedom to operate with modifications.
Key Takeaways
- The patent grants protection primarily over the composition and method of treatment in Canada.
- The claims are narrowly focused, emphasizing specific active concentrations and excipients.
- Existing patents in Canada cover different formulation features; overlapping rights are limited.
- Enforcement relies on the specific scope of claims and potential challenges based on prior art.
- Manufacturers should consider claim nuances when developing similar products to avoid infringement.
FAQs
1. Can this patent be challenged for invalidity?
Yes. Validity challenges may be based on lack of inventive step or novelty due to prior art references.
2. Does the patent cover only oral formulations?
Yes. The claims specify oral administration; other routes are not protected.
3. How long is the patent enforceable?
Until [date], assuming maintenance fees are paid on time.
4. Can a generic manufacturer develop a different formulation?
Yes, if they alter excipients, concentration, or formulation in a way not covered by the claims.
5. Is this patent enforceable across Canada?
Yes. Canadian patents are national rights, enforceable in courts throughout the country.
References
- Canadian Intellectual Property Office (CIPO). (2022). Patent database.
- WIPO. (2023). Guide to patent law in Canada.
- Lee, S. (2021). Pharmaceutical patent landscape analysis. Journal of Intellectual Property Law.
